KPNβ~1~, also known as importin-β, is part of the karyopherin superfamily of nuclear transport proteins.[@b1-ott-10-2067] The classical importin-α/β system is believed to import up to half of the nuclear traffic.[@b2-ott-10-2067] Importins and exportins transport pro-oncogenic mediators across the nuclear membrane and are found to be overexpressed in a number of cancer types, including breast, colon, esophageal, gastric, lung, lymphoma, melanoma, pancreatic, and prostate cancer.[@b3-ott-10-2067] The nuclear pore complex (NPC) is composed of approximately 30 proteins (nucleoporins) that are arranged octagonally around a central channel. KPNβ~1~ participates in the classical nuclear import pathway alongside its adaptor protein -- importin-α. Importin-α first recognizes and binds the cytoplasmic cargo via its nuclear localization signals, and then associates with importin-β via the importin-β binding (IBB) domain. This complex (nuclear localization signals--importin-α--importin-β) then traverses the nuclear pore complex.[@b4-ott-10-2067] This active transport is able to occur against the concentration gradient, due to varying levels of Ran, a GTPase.[@b4-ott-10-2067]

KPNβ~1~ has recently been shown to regulate proliferation of human glioma cells via the Wnt--β-catenin pathway.[@b5-ott-10-2067] Glioblastoma multiforme is the most frequent brain cancer in adults and is highly infiltrative.[@b6-ott-10-2067] Despite current treatments of neurosurgery and chemoradiotherapy, median survival remains around 14.6 months, and 5-year survival is \<5%.[@b5-ott-10-2067],[@b7-ott-10-2067] Lu et al showed that the relative expression of KPNβ~1~ correlated with the World Health Organization (WHO) grades of human glioma, with higher expression of KPNβ~1~ correlating with more severe WHO glioma classification.[@b5-ott-10-2067] Additionally, higher expression of KPNβ~1~ correlated with lower 5-year survival ratio on Kaplan--Meier survival curves.[@b5-ott-10-2067] Wnts are glycoproteins that are involved in cell proliferation, differentiation, and oncogenesis, and regulate β-catenin in their pathway.[@b5-ott-10-2067] KPNβ~1~ has recently been elucidated as a regulator of glioma-cell proliferation via the Wnt--β-catenin pathway.[@b5-ott-10-2067] Down-regulation of KPNβ~1~ has been shown to inhibit glioma proliferation in vitro. Additionally, cells with lower levels of KPNβ~1~ showed decreased nuclear β-catenin, demonstrating that KPNβ~1~ played a role in the nuclear transport of β-catenin in the Wnt--β-catenin pathway.[@b5-ott-10-2067] KPNβ~1~ has previously been shown to play a role in translocating β-catenin, which accelerates glioma proliferation.[@b5-ott-10-2067]

Another role of KPNβ~1~ and glioma is the transport of GLI1 into the nucleus.[@b8-ott-10-2067] GLI1 was discovered in human gliomata,[@b6-ott-10-2067] and is a nuclear regulator of the Hedgehog (Hh)-signaling pathway.[@b8-ott-10-2067] Dysregulation of this pathway leads to aggressive tumorigenesis. Hh normally binds to and inactivates Patched (Ptc). When Ptc is inhibited, Smoothened (Smo) is released and triggers a signaling cascade that ends in nuclear localization of GLI.[@b8-ott-10-2067] SuFu is an additional negative regulatory protein that anchors GLI in the cytoplasm during inactivation of the Hh-signaling pathway.[@b8-ott-10-2067]

KPNβ~1~ binds GLI1 with high affinity, and the GLI1-binding site on the N-terminus for SuFu overlaps with the GLI1-binding site for KPNβ~1~. This results in competitive binding of GLI1 based on relative concentrations of KPNβ~1~ and SuFu.[@b8-ott-10-2067] When KPNβ~1~ is bound to GLI1 (rather than SuFu bound to GLI1), GLI1 can undergo nuclear import and thereby play a role in tumorigenesis.[@b8-ott-10-2067] Various studies have found different levels of GLI1 in malignant gliomata. Zhu and Lo performed genome-wide copy-number analysis on 31 glioma samples and found that 22.6% of these samples had amplified *GLI1*.[@b6-ott-10-2067] Therefore, inhibition of nuclear import of GLI1 via KPNβ~1~ has the potential to inhibit oncogenesis in gliomata as a novel therapeutic strategy.[@b8-ott-10-2067] Interestingly, KPNβ~1~ has also been indicated in the development of secondary brain tumors.[@b9-ott-10-2067] Childhood acute lymphoblastic leukemia commonly results in treatment-related secondary brain tumors.[@b9-ott-10-2067] This is due in part to cranial irradiation (and treatment with antimetabolites), though a genetic predisposition is also necessary.[@b9-ott-10-2067] In a study by Edick et al, \~20% of patients developed secondary brain tumors, comprised of glioblastoma multiforme, anaplastic astrocytoma, primitive neuroectodermal tumors, and embryoplastic neuroepithelial tumors.[@b9-ott-10-2067] Genetic analysis of pretreatment acute lymphoblastic leukemia blasts indicated the *KPNB1* gene, along with *STAT4, NFIC,* and *HNRPL* (all involved in tumor growth and trafficking), to have high significance in the development of secondary brain tumors.[@b9-ott-10-2067] This supports the role of KPNβ~1~ in oncogenesis and cancer-cell viability and suggests its potential use as a predictive factor for secondary brain tumors. In conclusion, KPNβ~1~ is a promising target for anticancer therapeutics, including a potential for inhibition of certain neurological malignancies.
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